

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*

(Incorporated in Israel with limited liability)

(Stock code: 1696)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Sisram Medical Ltd (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Company has entered into a strategic partnership with Prollenium, a Canadian premium FDA-approved dermal filler manufacturer, to expand its injectables product portfolio and offer a unique combination of high-quality dermal filler with energy-based devices to enhance the effectiveness and longevity of various common aesthetic indications.

As part of the partnership arrangement, the Company will have exclusive distribution rights for the renowned Revanesse dermal filler collection in several key markets including Germany, Austria, Switzerland, Australia, and New Zealand.

Revanesse, Prollenium’s flagship product collection, consists of multipurpose dermal fillers that utilize advanced hyaluronic acid technology. These fillers are designed to restore volume, smooth wrinkles, correct and contour facial features.

The Company believes that the strategic partnership with Prollenium will strengthen the Company’s leadership in the non-invasive and minimally invasive medical aesthetic segment and empower the Company to pioneer cutting-edge solutions by combining advanced injectable products, which will improve the consumables revenue of the Company in the long term.

Shareholders and investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, January 8, 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU and Mr. Lior Moshe DAYAN as executive directors; Mr. Yifang WU and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* *For identification purpose only*